ThromboGenics Receives Notice from FDA of Advisory Committee Meeting for Ocriplasmin

Source: ThromboGenics NV
ThromboGenics NV announced that the US Food and Drug Administration has notified the company that its new biologic license application for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.

Ocriplasmin is an investigational biological drug candidate intended for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.

ThromboGenics resubmitted its BLA for ocriplasmin in April 2012 in anticipation of it being granted Priority Review by the FDA.

Related Content